MedReleaf Approval for 2nd Facility Boosts Cannabis Production Capacity to 12.6 Million Grams

MedReleaf receives license amendment from Health Canada to commence sales at its Bradford Facility

Construction and capacity expansion firmly on track

MARKHAM, ON, Nov. 6, 2017 /CNW/ – MedReleaf Corp. (TSX:LEAF) (“MedReleaf” or the “Company”), Canada’s first and only ISO 9001 and ICH-GMP certified producer of medical cannabis, has been granted an amended licence from Health Canada to permit sales of medical cannabis under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”) at its second facility in Bradford, ON (“Bradford Facility”). This increases the Company’s total current licensed production and sales capacity by 80% to approximately 12,600 kg per year.

Just 6 months after receiving our cultivation licence at Bradford, we are among the fastest producers to receive a sales licence and have completed multiple harvests at best-in-class cultivation yields of 300 grams per square foot. As our industry grows, our proven ability to execute large scale projects while maintaining the highest quality standards further solidifies MedReleaf as a trusted leader amongst licensed producers.

Neil Closner, CEO of MedReleaf

This latest amended license from Health Canada follows several other recent milestones at the Bradford Facility. On October 11, 2017, MedReleaf received its amended licence for the use of its Mother Room and Clone Room which will support the growing capacity at the Bradford Facility. On October 20, 2017, the Company received an amended licence for the use of two additional cultivation rooms, effectively doubling annual production capacity to an estimated 5,600 kg at the Bradford Facility. Once construction of the Bradford Facility is fully completed in the summer of 2018, total licensed production and sales capacity from MedReleaf’s two facilities in Markham and Bradford will be 35,000 kg per year.

About MedReleaf Corp.

MedReleaf sets The Medical Grade Standard™ for cannabis in Canada and around the world. The first and only ICH-GMP and ISO 9001 certified cannabis producer in North America, MedReleaf is a R&D-driven company dedicated to patient care, scientific innovation, research and advancing the understanding of the therapeutic benefits of cannabis. Sourced from around the world and perfected in one of two state of the art facilities in Ontario, MedReleaf delivers a variety of premium products to patients seeking safe, consistent and effective medical cannabis.

For more information on MedReleaf, its products, research and how the company is helping patients #livefree, please visit MedReleaf.com or follow @medreleaf

Original press release

Get ahead of the crowd by signing up for 420 Investor, the largest & most comprehensive premium subscription service for cannabis traders and investors since 2013.

Published by NCV Newswire
NCV Newswire
The NCV Newswire by New Cannabis Ventures aims to curate high quality content and information about leading cannabis companies to help our readers filter out the noise and to stay on top of the most important cannabis business news. The NCV Newswire is hand-curated by an editor and not automated in anyway. Have a confidential news tip? Get in touch.

Get Our Sunday Newsletter